- Di sistema
- Liquid biopsy represents one of the most promising innovations in precision medicine, offering the possibility to non-invasively analyze dynamic biological signals useful for early diagnosis, prognostic stratification, and monitoring disease evolution. Advances in sequencing technologies, refinement of cfdna and ctdna analyses, and the integration of increasingly sensitive computational models are significantly expanding the potential of this approach.
The congress therefore aims to consolidate a cohesive scientific community, promote the circulation of new evidence, discuss sustainable organizational models, and define priorities for the implementation of liquid biopsy across different care pathways. A moment of discussion that marks the beginning of a structured and shared journey toward a future of increasingly precise and timely diagnosis and monitoring.